Laminar Pharma completes last patient visit in Phase 2b/3 LAM561 glioblastoma trial

The company said topline results are expected in the second quarter of 2027 after data lock and overall survival analysis in the 144-patient study.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.